

## Perspectives

- The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition.**  
David J. McConkey and Colin P. Dinney ..... 1001  
*Perspective on Seager et al., p. 1008*
- Is It Time to Advance the Chemoprevention of Environmental Carcinogenesis with Microdosing Trials?** Thomas W. Kensler and John D. Groopman ..... 1003  
*Perspective on Jubert et al., p. 1015*

## Research Articles

- Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer.** Catherine M. Seager, Anna M. Puzio-Kuter, Trushar Patel, Shalini Jain, Carlos Cordon-Cardo, James Mc Kiernan, and Cory Abate-Shen ..... 1008
- Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B<sub>1</sub> Pharmacokinetics in Human Volunteers.** Carole Jubert, John Mata, Graham Bench, Roderick Dashwood, Cliff Pereira, William Tracewell, Kenneth Turteltaub, David Williams, and George Bailey ..... 1015
- Gender Modifies the Effect of Ursodeoxycholic Acid in a Randomized Controlled Trial in Colorectal Adenoma Patients.** Patricia A. Thompson, Betsy C. Wertheim, Denise J. Roe, Erin L. Ashbeck, Elizabeth T. Jacobs, Peter Lance, María Elena Martínez, and David S. Alberts ..... 1023
- Dietary Tricin Suppresses Inflammation-Related Colon Carcinogenesis in Male Crj: CD-1 Mice.** Takeru Oyama, Yumiko Yasui, Shigeyuki Sugie, Mamoru Koketsu, Kunitomo Watanabe, and Takuji Tanaka ..... 1031
- EphA2 in the Early Pathogenesis and Progression of Non-Small Cell Lung Cancer.** Jennifer M. Brannan, Banibrata Sen, Babita Saigal, Ludmila Prudkin, Carmen Behrens, Luisa Solis, Wenli Dong, B. Nebiyu Bekele, Ignacio Wistuba, and Faye M. Johnson ..... 1039
- Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice.** Karen Liby, Renee Risingsong, Darlene B. Royce, Charlotte R. Williams, Tian Ma, Mark M. Yore, and Michael B. Sporn ..... 1050
- Preventive Effects of Bexarotene and Budesonide in a Genetically Engineered Mouse Model of Small Cell Lung Cancer.** Yian Wang, Weidong Wen, Yijun Yi, Zhongqiu Zhang, Ronald A. Lubet, and Ming You ..... 1059
- Lack of Evidence for Green Tea Polyphenols as DNA Methylation Inhibitors in Murine Prostate.** Shannon R. Morey Kinney, Wa Zhang, Marien Pascual, John M. Grealley, Bryan M. Gillard, Ellen Karasik, Barbara A. Foster, and Adam R. Karpf ..... 1065
- Distinct Effects of Calorie Restriction and Exercise on Mammary Gland Gene Expression in C57BL/6 Mice.** Michela Padovani, Jackie A. Lavigne, Gadisetti V.R. Chandramouli, Susan N. Perkins, J. Carl Barrett, Stephen D. Hursting, L. Michelle Bennett, and David Berrigan ..... 1076
- The Cyclooxygenase Inhibitor Sulindac Sulfide Inhibits EP4 Expression and Suppresses the Growth of Glioblastoma Cells.** Atsushi Kambe, Hiroki Yoshioka, Hideki Kamitani, Takashi Watanabe, Seung Joon Baek, and Thomas E. Eling ..... 1088
- A DNA Methyltransferase Inhibitor and All-trans Retinoic Acid Reduce Oral Cavity Carcinogenesis Induced by the Carcinogen 4-Nitroquinoline 1-Oxide.** Xiao-Han Tang, Martin Albert, Theresa Scognamiglio, and Lorraine J. Gudas ..... 1100


## Reviewers

- Acknowledgement to Reviewers.** ..... 1111

---

## About the Cover

The cover photographs illustrate the dramatic suppression of muscle-invasive bladder cancer by intravesically administered rapamycin, which inhibits the mammalian target of rapamycin (mTOR), in a genetically engineered mouse model of progression from pre-invasive to invasive bladder cancer. The larger, muscle-invasive tumor (top) developed in a mouse treated with control vehicle; the smaller, non-muscle-invasive tumor (bottom) developed in a mouse treated with rapamycin. The measures numbered along the  $x$  and  $y$  axes are centimeters. These findings are the first to demonstrate the chemopreventive effectiveness of a molecular-targeted agent given intravesically in a relevant murine bladder cancer model; they support broadening the study of intravesical therapeutic agents in high-risk non-muscle-invasive bladder cancer patients and provide a preclinical mouse model for testing novel such agents. Showing that intravesical delivery of an mTOR inhibitor blocks progression to invasive disease provides new hope for patients at a high risk for developing muscle-invasive bladder cancer, for whom few treatment options exist. See articles by Seager et al. (beginning on page 1008) and McConkey and Dinney (beginning on page 1001) for more information.



# Cancer Prevention Research

2 (12)

*Cancer Prev Res* 2009;2:1001-1112.

**Updated version** Access the most recent version of this article at:  
<http://cancerpreventionresearch.aacrjournals.org/content/2/12>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/2/12>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.